Coexisting chronic obstructive pulmonary disease and heart failure: Implications for treatment, course and mortality

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 2, 2010, Pages 106-111

  Mascarenhas, Joana ^a,b   Azevedo, Ana ^a,b,c   Bettencourt, Paulo ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b Unidade de Investigação e Desenvolvimento Cardiovascular Do Porto   (Portugal)

^c University of Porto   (Portugal)

Author keywords

blockers; Chronic obstructive pulmonary disease; Heart failure; Prognosis

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE COURSE; HEART FAILURE; HUMAN; MORTALITY; PRESCRIPTION; PROGNOSIS; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; COMORBIDITY; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 76449092403     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328335dc90     Document Type: Review

References (61)

1. GOLD, Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report 2006. http://www.gold copd.com/.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failures 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ECSIM). Eur Heart J 2008; 29:2388-2442.
3. Padeletti M, Jelic S, LeJemtel TH. Coexistent chronic obstructive pulmonary disease and heart failure in the elderly. Int J Cardiol 2008; 125:209-215.
4. Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006; 8:706-711.
5. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11:130-139.
6. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370:741-750.
7. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355. (Pubitemid 26152713)
8. The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
9. The CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353:9-13.
10. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49:171-180.
11. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97:1094-1101.
12. Komajda M, Follath F, Swedberg K, et al., The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24:464-474. (Pubitemid 36286188)
13. Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med 2005; 98:493-497.
14. Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007; 9:1205-1211.
15. Rusinaru D, Saaidi I, Godard S, et al. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101:353-358.
16. Lainscak M, Hodoscek LM, Düngen HD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009; 121:309-313.
17. Macchia A, Monte S, Romero M, et al. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007; 9:942-948.
18. Curkendall SM, DeLuise J, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16:63-70.
19. Sidney S, Sorel M,Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128:2068-2075.
20. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26:1887-1894.
21. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of Btype natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10:198-204.
22. Ni H, Nauman DJ, Hershberger RE. Managed care and outcomes of hospitalization among elderly patients with congestive heart failure. Arch Intern Med 1998; 158:1231-1236.
23. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
24. Havranek EP, Masondi FA, Westfall KA, et al. Spectrum of heart failure in older patients: results from National Heart Failure project. Am Heart J 2002; 143:412-417.
25. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42:1226-1233.
26. Gustafsson F, Torp-Pedersen C, Burchardt H, et al. Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. Eur Heart J 2004; 25:129-135.
27. Mascarenhas J, Lourenço P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008; 155:521-525.
28. Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 2008; 264: 361-369.
29. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123:1684-1692.
30. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006; 51:1120-1124.
31. Parker AB, Yusuf S, Naylor CD. The relevance of subgroup-specific treatment effects: the studies of left ventricular dysfunction (SOLVD) revisited. Am Heart J 2002; 144:941-947.
32. Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-Heft heart failure trial. J Card Fail 2007; 13:797-804.
33. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291:1963-1971.
34. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541-1547.
35. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519.
36. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33:1-21.
37. Dahlström U. Frequent noncardiac comorbidities in patients with chronic heart failure. Eur J Heart Fail 2005; 7:309-316.
38. Azevedo A, Bettencourt P, Pimenta J, et al. Clinical syndrome suggestive of heart failure is frequently attributable to noncardiac disorders: populationbased study. Eur J Heart Fail 2007; 9:391-396.
39. Harrington RA, Jones K. ABC of clinical electrocardiography. Conditions affecting the right side of the heart. BMJ 2002; 324:1201-1204.
40. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125:669-682.
41. Rutten FH, Moons KGM, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005; 331:1379.
42. Boussuges A, Pinet C, Molenat F, et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med 2000; 162:670-675.
43. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications of cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 2004; 25:1940-1965.
44. Bettencourt PM. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart 2005; 91:1489-1494.
45. Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Curr Opin Crit Care 2008; 14:340-347.
46. Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. Eur J Heart Fail 2009; 11:85-91.
47. Villar Alvarez F, Méndez Bailó n M, de Miguel Díez J. Chronic obstructive pulmonary disease and heart failure. Arch Bronconeumol 2009; 45:387-393.
48. Ashrafian H, Violaris AG. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. Prim Care Respir J 2005; 14:236-241.
49. van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of betablockers in COPD: a concern for nonselective beta-blockers. Chest 2005; 127:818-824.
50. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: nonselective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44:497-502.
51. Kotlyar E, Keogh AM, MacDonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21:1290-1295.
52. The Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12:10-38.
53. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009; 11:684-690.
54. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax 2003; 58:556-558.
55. Casaburi R, Mahler DA, Jones PW, et al. A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Resp J 2002; 19:217-224.
56. Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003; 123:1964-1969.
57. Hirono O, Kubota I, Minamihaba O, et al. Left ventricular diastolic dysfunction in patients with bronchial asthma with long-term oral beta2-adrenoreceptor agonists. Am Heart J 2001; 142:E11.
58. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309-2321.
59. Calverley PM, Anderson JA, Celli B, et al., TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
60. Holguim F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128:2005-2011.
61. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2:8-11.